Diseases & Conditions Market Research Reports & Industry Analysis
Insomnia is a common condition in which one has trouble going to sleep or staying asleep. This condition can range from weak to strong, depending on how often it occurs and for how long. Insomnia can be ongoing or acute. Chronic insomnia means having symptoms at least 3 nights a week for more than a month. Acute insomnia lasts for less time. Some people who have insomnia will have trouble falling asleep. Other people may fall asleep easily but, then wake up.
Diseases & Conditions Industry Research & Market Reports
-
Blood Cancer Diagnostics
... at a CAGR of 5.4% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$8.4 Billion by the end of the ... Read More
-
Ovarian Cancer Diagnostics
... at a CAGR of 3.5% over the analysis period 2024-2030. Epithelial Tumor, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Blood Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Chronic Myeloid Leukemia (CML), one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$13.6 Billion by the ... Read More
-
Prostate Cancer Devices
... at a CAGR of 9.8% over the analysis period 2024-2030. Radiation Treatment Devices, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$3.1 Billion by the end ... Read More
-
Follicular Thyroid Cancer Drugs
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Papillary Carcinoma Type, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$515.5 Million by ... Read More
-
Clinical Nutrition for Cancer Care
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Oral Nutrition Type, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$3.0 ... Read More
-
Thyroid Cancer Diagnostics
... at a CAGR of 3.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$4.0 Billion by the end of the ... Read More
-
Cancer Therapeutics and Biotherapeutics
... 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$64.0 Billion by the ... Read More
-
Over-the-Counter Pain Medication
... at a CAGR of 2.7% over the analysis period 2024-2030. Non-steroidal Anti-inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$12.1 Billion by the end ... Read More
-
Gastric Cancer Diagnostics
... at a CAGR of 3.5% over the analysis period 2024-2030. Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.0 Billion by the end ... Read More
-
Fabry Disease Treatment
... at a CAGR of 8.2% over the analysis period 2024-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$1.7 Billion by the end ... Read More
-
Intravenous Immunoglobulin (IVIg)
... at a CAGR of 8.5% over the analysis period 2024-2030. IgA, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Chronic Obstructive Pulmonary Disease (COPD) Treatment
... reach US$27.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Combination, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$15.9 ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Allergy Treatment
... CAGR of 3.7% over the analysis period 2024-2030. Asthma, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$5.9 Billion by the end of the analysis period. ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Limestone
... 3.9% over the analysis period 2024-2030. Construction, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$84.8 Billion by the end of the analysis period. Growth in ... Read More
-
Oral Antivirals
... CAGR of 1.5% over the analysis period 2024-2030. Human Immunodeficiency Virus, one of the segments analyzed in the report, is expected to record a 1.0% CAGR and reach US$18.0 Billion by the end of the ... Read More
-
Self-Leveling Concrete
... CAGR of 4.3% over the analysis period 2024-2030. Underlayment, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$7.0 Billion by the end of the analysis period. ... Read More
-
Osteoarthritis Therapeutics
... CAGR of 7.3% over the analysis period 2024-2030. Knee, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.1 Billion by the end of the analysis period. ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in ... Read More
-
Insulin Patch Pumps
... at a CAGR of 9.8% over the analysis period 2024-2030. Basal & Bolus, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$1.4 Billion by the end ... Read More
-
Insulin Storage Devices
... at a CAGR of 7.5% over the analysis period 2024-2030. Battery Operated Devices, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$996.0 Million by the end ... Read More
-
Infectious Disease Therapeutics
... at a CAGR of 7.1% over the analysis period 2024-2030. HIV, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$113.7 Billion by the end of the ... Read More
-
Immunomodulators
... 5.7% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$209.8 Million by the end of the analysis period. Growth in ... Read More
Research Assistance
